CAR-T Cell Therapy Resource Center
News & Information for Healthcare Professionals
CAR T-Cell Therapy HCP Guide – Side Effects: Cerebral Edema
Cerebral edema (brain swelling) is another very serious and often fatal adverse event encountered with CAR T treatment.
Eight cerebral edema-related deaths have been reported...
CAR T-Cell Therapy HCP Guide – Side Effects: Neurotoxicity
Neurotoxicity, which can occur in tandem with cytokine release syndome (CRS), includes symptoms such as aphasia, tremor, and seizures. Other reported CNS events include...
CAR T-Cell Therapy HCP Guide – Side Effects: Cytokine Release Syndrome (CRS)
Cytokine Release Syndrome (CRS) is one of the most common, but worrisome, serious side effects of CAR T-cell therapy. How does it occur? After...
CAR T-Cell Therapy HCP Guide – Overview: Side Effects from CAR T-Cell Therapy
CAR T-cell therapy is a potent investigational treatment used in patients with high tumor burden. A positive response to CAR T-cell therapy leads to...
T Cells Expressing a Novel Fully-Human Anti-CD19 Chimeric Antigen Receptor Induce Remissions of Advanced...
December 1, 2016 (Blood)
"Chimeric antigen receptors (CARs) are fusion proteins that combine antigen-recognition domains and T-cell signaling domains."
T cells harvested from patients' blood...
CAR T-Cell Therapy Can Now Target Solid Tumors: Mouse Study
June 21, 2016 (Medical News Today)
In Phase 2 trials, chimeric antigen receptors (CARs), genetically engineered protein constructs, rewire T-cells in a patient’s own immune...
StatPearls Question of the Week – #6
To date in clinical trials, chimeric antigen receptor T (CAR-T) cell therapy has been used to treat which type of cancer?
A. Sezary syndrome
B....
CAR T-Cell Therapy HCP Guide – Solid Tumor Research: Progress to Be Made
While CAR T-cell therapy in hematologic cancers is impressive, the fact remains that most deadly cancers are solid tumors like lung, breast, or colon...
CAR T-Cell Therapy HCP Guide – Pivotal Trial: Aggressive B-Cell Non-Hodgkin Lymphoma
Aggressive B Cell Non-Hodgkin Lymphomas
About 90% of lymphoma cases start in the B cells. The C19 tumor target that is sought by the...
CAR T-Cell Therapy HCP Guide – Cancer Targets
Gene Therapy to the Rescue
The first investigational oncology gene therapy known as a chimeric antigen receptor (CAR) T-cell therapy is rapidly moving...
